Scarica l'app Stockscreener
2.30
2.95%
-0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.37
Aprire:
$2.34
Volume 24 ore:
4,929
Relative Volume:
0.26
Capitalizzazione di mercato:
$15.32M
Reddito:
$105.38M
Utile/perdita netta:
$17.78M
Rapporto P/E:
0.8614
EPS:
2.67
Flusso di cassa netto:
$-50.48M
1 W Prestazione:
-5.35%
1M Prestazione:
-15.44%
6M Prestazione:
-24.09%
1 anno Prestazione:
-43.63%
Intervallo 1D:
$2.30
$2.3538
Intervallo di 1 settimana:
$2.30
$2.45
Portata 52W:
$2.30
$4.16
Mei Pharma Inc Stock (MEIP) Company Profile
Nome
Mei Pharma Inc
Settore
Industria
Telefono
858-369-7100
Indirizzo
11455 EL CAMINO REAL, SAN DIEGO, CA
Confronta MEIP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MEIP
Mei Pharma Inc
|
2.30 | 15.32M | 105.38M | 17.78M | -50.48M | 2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Mei Pharma Inc Stock (MEIP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-23 | Downgrade | Laidlaw | Buy → Hold |
| 2022-03-25 | Downgrade | Jefferies | Buy → Hold |
| 2022-03-25 | Downgrade | Stifel | Buy → Hold |
| 2022-03-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-02-03 | Iniziato | Jefferies | Buy |
| 2020-09-22 | Iniziato | Alliance Global Partners | Buy |
| 2020-05-29 | Iniziato | SunTrust | Buy |
| 2018-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2018-07-27 | Aggiornamento | Stifel | Hold → Buy |
| 2018-07-13 | Iniziato | SunTrust | Buy |
| 2016-04-18 | Reiterato | Wedbush | Neutral |
| 2015-03-23 | Downgrade | ROTH Capital | Buy → Neutral |
| 2014-12-18 | Reiterato | ROTH Capital | Buy |
| 2014-10-16 | Reiterato | ROTH Capital | Buy |
| 2014-07-08 | Ripresa | Brean Capital | Buy |
| 2013-10-22 | Reiterato | Stifel | Buy |
| 2013-04-15 | Iniziato | Stifel | Buy |
Mostra tutto
Mei Pharma Inc Borsa (MEIP) Ultime notizie
MEI Pharma, Inc. to Host Earnings Call - ACCESS Newswire
StockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
10 Cheap Chinese Stocks to Buy Now - Insider Monkey
11 Best Undervalued Stocks to Invest in Now - Insider Monkey
MEI Pharma (NASDAQ:MEIP) Coverage Initiated at StockNews.com - Defense World
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight - The Malaysian Reserve
C-COM Antenna Receives Eutelsat Type Approval - The Globe and Mail
Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Alarm.com (ALRM) Q4 Earnings: What To Expect - The Globe and Mail
Why Tight Corporate-U.S. Treasury Yield Spreads Signal Good News for Ag Markets Prices - The Globe and Mail
MEI Pharma (NASDAQ:MEIP) Coverage Initiated by Analysts at StockNews.com - Defense World
MEI Pharma Reports Increased Losses Amid Strategic Shift - TipRanks
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position - BioSpace
MEI Pharma Inc. (MEIP) reports earnings - Quartz
MEI Pharma, Inc. SEC 10-Q Report - TradingView
Geriatric Population And Unmet Healthcare Needs Fuel Growth In Acute Myeloid Leukemia Market: A Key Driver ... - WhaTech
Malt Lymphoma Pipeline 2024: Detailed Clinical Trials - openPR
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $43.60 Average Target Price from Analysts - Defense World
No Headlines, No Problem: Why Technical Analysis Still Moves Stocks - The Globe and Mail
Layoff Tracker: Viracta, X4 and BMS Detail Current, Upcoming Cuts - BioSpace
Protein Bar Launch in Convenience Channel, Sending Shares of this MicroCap Higher - The Globe and Mail
MEI Pharma (NASDAQ:MEIP) Earns Buy Rating from Analysts at StockNews.com - Defense World
3 Easy Ways to Build Up Your Portfolio in 2025 - The Globe and Mail
Scientist pleads guilty to stealing trade secrets for Chinese pharma company - Fox28 Savannah
Kimberly-Clark: A Regal Opportunity in This Dividend King - The Globe and Mail
ROSEN, A LEADING LAW FIRM, Encourages Infinity Pharmaceuticals, - GuruFocus.com
Will PepsiCo Hike Its Dividend Soon?Looks LikelyValue Investors Love the Stock - The Globe and Mail
MEI Pharma (NASDAQ:MEIP) Now Covered by StockNews.com - Defense World
Assenagon Asset Management S.A. Buys 2,285 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
B-cell Non-hodgkin Lymphoma Clinical and Non-Clinical - openPR
Follicular Lymphoma Market Expected to rise, 2034 | Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corp - The Globe and Mail
Jane Street Group LLC Buys 7,126 Shares of Semler Scientific, Inc. (NASDAQ:SMLR) - Defense World
Liquid Mushroom Market is Expected to Rise at CAGR of 6% to Reach US$ 15.74 Billion by 2034 | Fact.MR Report - GlobeNewswire Inc.
MEI Pharma stock hits 52-week low at $2.4 amid market challenges - Investing.com Canada
MEI Pharma stock hits 52-week low at $2.54 amid market challenges - Investing.com Australia
4 Reasons to Buy Uber Stock Like There's No Tomorrow - The Globe and Mail
MEI Pharma (LTS:0JW9) 5-Day RSI : 36.09 (As of Dec. 05, 2024) - GuruFocus.com
MEIP (MEI Pharma) Financial Strength : 7 (As of Sep. 2024) - GuruFocus.com
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
MEI Pharma (LTS:0JW9) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
Deal Dispatch: Starbucks Explores China Sale, PE Firms Saddle Snack Company With DebtAmcor (NYSE:AMCR), Berry Global Gr (NYSE:BERY) - Benzinga
Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul - Benzinga
MEI Pharma Reports Strategic Shift Amid Financial Losses - TipRanks
MEI Pharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com
MEI Pharma reports Q1 EPS ($1.20) vs. $8.46 last year - TipRanks
MEI Pharma Explores Strategic Sale Amid Cash Preservation Efforts, Reports $26.9M Cash Position | MEIP Stock News - StockTitan
Acute Myeloid Leukemia (AML) Treatment Market in APAC to Grow by USD 305.8 Million from 2024-2028, Driven by High Incidence and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Mei Pharma Inc Azioni (MEIP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.39%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):